CDMO– tag –
-
AGC Biologics Secures Landmark Multi-Hundred-Million-Dollar Deal for Yokohama Facility, Cementing Japan’s Biologics Manufacturing Leadership
AGC Biologics Japan Overview AGC Biologics has secured a multi-year, multi-hundred-million-dollar commercial manufacturing agreement for its new Yokohama facility, slated to open in 2027. This landmark deal dedicates approximately half o... -
Reusable Bioreactor Market Surges: Driven by Large-Volume Biologics Production and CDMO Capacity Expansion, Hybrid Manufacturing Emerges
Constancy Researchers USA Overview The reusable bioreactor market is experiencing substantial growth, propelled by the increasing demand for large-volume commercial biopharmaceutical production and the expansion of CDMO capacities. A not... -
Biopharmaceuticals Contract Manufacturing Market Expands Amid Global Demand: CDMOs Scale Up Capacity
openPR.com Unknown Overview This article provides an overview of a market research report published by openPR.com. The biopharmaceutical contract manufacturing market is growing due to increased demand for biosimilars, expanded investmen... -
Lonza Reports Robust Cell and Gene Therapy Sector Growth in H1 2026 Earnings, Driven by CDMO Contracts and Facility Utilization
Lonza Switzerland Overview Lonza announced strong growth in its cell and gene therapy division in the first half of 2026 earnings, propelled by an increase in new CDMO contracts and improved utilization of existing manufacturing faciliti... -
Thermo Fisher Scientific Dramatically Expands Global Cell and Gene Therapy CDMO Manufacturing Capacity with Enhanced Automation
Thermo Fisher Scientific USA Overview Thermo Fisher Scientific has significantly expanded its global manufacturing network for cell and gene therapy products to meet surging demand. This strategic move aims to provide advanced manufactur... -
BioPharma Dive Reports on Cell and Gene Therapy Manufacturing Frontlines: Viral Vector Supply Shortages and CDMO Market Soaring to $9.08 Billion by 2031
BioPharma Dive USA Overview BioPharma Dive analyzes key challenges and commercial opportunities in cell and gene therapy manufacturing, pinpointing viral vector production as the most severe supply constraint. Lonza is significantly expa... -
Kincell Bio Inaugurates and Expands State-of-the-Art GMP Cell Therapy Manufacturing Facilities in Gainesville and Research Triangle Park
Kincell Bio USA Overview Kincell Bio has opened and expanded GMP cell therapy manufacturing facilities in Gainesville, Florida, and Research Triangle Park, North Carolina, designed to support both autologous and allogeneic cell therapies... -
OXB Accelerates Gene Therapy Production for Plowshare Therapies, Leveraging FDA-Approved AAV Manufacturing in North Carolina
Markets Insider UK Overview OXB has partnered with Plowshare Therapies to provide crucial process development and GMP manufacturing for Plowshare’s AAV gene therapy program. This collaboration leverages OXB's FDA-approved commercial-scal... -
Continuous Bioprocessing Delivers Significant Gains in Biopharmaceutical Manufacturing Efficiency and Cost Reduction, Driven by 500L Single-Use Perfusion Bioreactors
BioProcess International USA Overview Biopharmaceutical manufacturers are rapidly adopting continuous bioprocessing, integrating upstream cell culture and downstream operations to boost productivity, cut costs, and reduce facility footpr... -
Kincell Bio Unveils Scalable Allogeneic Cell Therapy Manufacturing Platform for Large-Scale Production with Closed-System Automation
Kincell Bio USA Overview Kincell Bio has launched a scalable allogeneic cell therapy manufacturing platform designed for large-volume production, efficient cell expansion, and closed-system automation. This platform supports diverse cell...
